Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Haimerl, Michael ^a   Verloh, Niklas ^a   Zeman, Florian ^a   Fellner, Claudia ^a   Müller Wille, René ^a   Schreyer, Andreas G ^a   Stroszczynski, Christian ^a   Wiggermann, Philipp ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASE-CONTROL STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84893541813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085658     Document Type: Article

References (35)

1. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838-851. doi:10.1016/S0140-6736(08)60383-9. PubMed: 18328931. (Pubitemid 351323895)
2. Schuppan D, Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901. doi:10.1172/JCI66028. PubMed: 23635787.
3. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N et al. (2010) Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 40: 1-7. doi:10.1111/j.1872-034X.2009.00633.x. PubMed: 20156295.
4. Kim AI, Saab S (2005) Treatment of hepatitis C. Am J Med 118: 808-815. doi:10.1016/j.amjmed.2005.01.073. PubMed: 16084169. (Pubitemid 41097454)
5. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618. doi:10.1111/j.1572- 0241.2002.06038.x. PubMed: 12385448.
6. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293. doi:10.1002/hep.510240201. PubMed: 8690394. (Pubitemid 26260021)
7. Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K et al. (2013) Noninvasive evaluation of hepatic fibrosis in HCV-infected patients using EOB-MR imaging. J Gastroenterol Hepatol.
8. Bota S, Sporea I, Sirli R, Popescu A, Danila M et al. (2012) Intra- and interoperator reproducibility of acoustic radiation force impulse (ARFI) elastography - preliminary results. Ultrasound Med Biol 38: 1103-1108. doi:10.1016/j.ultrasmedbio.2012.02.032. PubMed: 22579536.
9. Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A et al. (2009) Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 193: 1053-1060. doi:10.2214/AJR.08.1946. PubMed: 19770329.
10. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn. Reson - Med Sci 6: 43-52. doi:10.2463/mrms.6.43.
11. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B et al. (2008) Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18: 1577-1586. doi:10.1007/s00330-008-0929- 6. PubMed: 18369632.
12. Tamada T, Ito K, Higaki A, Yoshida K, Kanki A et al. (2011) Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 80: e311-e316. doi:10.1016/j.ejrad. 2011.01.020. PubMed: 21315529.
13. Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J et al. (2005) Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 237: 89-98. doi:10.1148/radiol. 2371031842. PubMed: 16126918. (Pubitemid 41346150)
14. Hamm B, Staks T, Mühler A, Bollow M, Taupitz M et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195: 785-792. PubMed: 7754011.
15. Tsuda N, Matsui O (2010) Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. Radiology 256: 767-773. doi:10.1148/radiol.10092065. PubMed: 20663976.
16. Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42: 242-247. doi:10.1097/01.rli.0000258058.44876.a5. PubMed: 17351431. (Pubitemid 46398863)
17. Katsube T, Okada M, Kumano S, Hori M, Imaoka I et al. (2011) Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 46: 277-283. doi:10.1097/RLI.0b013e318200f67d. PubMed: 21343827.
18. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 29: 1725-1748. doi:10.1148/rg.296095515. PubMed: 19959518.
19. Malhi H, Gores GJ (2008) Cellular and molecular mechanisms of liver injury. Gastroenterology 134: 1641-1654. doi:10.1053/j.gastro.2008.03.002. PubMed: 18471544. (Pubitemid 351615416)
20. Tsuda N, Harada K, Matsui O (2011) Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroenterol Hepatol 26: 568-576. doi:10.1111/j.1440-1746.2010.06494.x. PubMed: 21332553.
21. Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T et al. (2003) Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38: 345-354. doi:10.1053/jhep.2003.50317. PubMed: 12883478. (Pubitemid 36919855)
22. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T et al. (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45: 133-141. doi:10.1097/RLI.0b013e3181caea5b. PubMed: 20098330.
23. Kreft B, Dombrowski F, Block W, Bachmann R, Pfeifer U et al. (1999) Evaluation of different models of experimentally induced liver cirrhosis for MRI research with correlation to histopathologic findings. Invest Radiol 34: 360-366. doi:10.1097/00004424-199905000-00006. PubMed: 10226849. (Pubitemid 29198346)
24. Goldberg HI, Moss AA, Stark DD, McKerrow J, Engelstad B et al. (1984) Hepatic cirrhosis: magnetic resonance imaging. Radiology 153: 737-739. PubMed: 6494469. (Pubitemid 15190051)
25. Ito K, Mitchell DG, Gabata T, Hann HW, Kim PN et al. (1999) Hepatocellular carcinoma: association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology 212: 235-240. doi:10.1148/radiology. 212.1.r99jl41235. PubMed: 10405747. (Pubitemid 29302541)
26. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218. doi:10.1172/JCI200524282. PubMed: 15690074. (Pubitemid 40385459)
27. Thomsen C, Christoffersen P, Henriksen O, Juhl E (1990) Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging 8: 599-604. doi:10.1016/0730-725X(90)90137-Q. PubMed: 2082130.
28. Heye T, Yang SR, Bock M, Brost S, Weigand K et al. (2012) MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 22: 1224-1232. doi:10.1007/s00330-012-2378-5. PubMed: 22302503.
29. Aisen AM, Doi K, Swanson SD (1994) Detection of liver fibrosis with magnetic cross-relaxation. Magn Reson Med 31: 551-556. doi:10.1002/mrm. 1910310513. PubMed: 8015410. (Pubitemid 24129951)
30. Chow AM, Gao DS, Fan SJ, Qiao Z, Lee FY et al. (2012) Measurement of liver T(1) and T(2) relaxation times in an experimental mouse model of liver fibrosis. J Magn Reson Imaging 36: 152-158. doi:10.1002/jmri.23606. PubMed: 22334510.
31. Lee JK, Glazer HS (1990) Controversy in the MR imaging appearance of fibrosis. Radiology 177: 21-22. PubMed: 2399319. (Pubitemid 20317315)
32. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210. doi:10.1002/path.2277. PubMed: 18161745.
33. Chamuleau RA, Creyghton JH, De Nie I, Moerland MA, Van der Lende OR et al. (1988) Is the magnetic resonance imaging proton spin-lattice relaxation time a reliable noninvasive parameter of developing liver fibrosis? Hepatology 8: 217-221. doi:10.1002/hep.1840080204. PubMed: 3356402.
34. Aubé C, Moal F, Oberti F, Roux J, Croquet V et al. (2007) Diagnosis and measurement of liver fibrosis by MRI in bile duct ligated rats. Dig Dis Sci 52: 2601-2609. doi:10.1007/s10620-006-9143-z. PubMed: 17429735. (Pubitemid 47373868)
35. Kim KA, Park MS, Kim IS, Kiefer B, Chung WS et al. (2012) Quantitative evaluation of liver cirrhosis using T1 relaxation time with 3 tesla MRI before and after oxygen inhalation. J Magn Reson Imaging 36: 405-410. doi:10.1002/jmri.23620. PubMed: 22392835.